Related Experiment Video
Updated: May 5, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Comparative Preclinical Evaluation of BIX-01294 and UNC0642 as EHMT2-Targeting Anticancer Agents
Sang Eun Park1,2, Ji-Yoon Lee1, Unju Lee1,2
1Asan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of Korea.
Background:
EHMT2 (G9a) is a key epigenetic regulator frequently overexpressed in various cancers. While several inhibitors exist, their in vivo efficacy and pharmacokinetic (PK) properties remain poorly characterized.
Methods:
We compared the biochemical, cellular, and PK profiles of two widely used EHMT2 inhibitors, BIX-01294 and UNC0642, and evaluated their antitumor efficacy in xenograft and syngeneic mouse models.
Results:
Despite a higher enzymatic potency of UNC0642 (IC50 = 0.277 μM) compared to BIX-01294 (IC50 = 1.983 μM), BIX-01294 demonstrated superior cellular growth inhibition and higher intracellular accumulation. PK analysis further revealed that BIX-01294 achieved higher systemic exposure (AUC) and a wider therapeutic window via intraperitoneal administration, whereas UNC0642 exhibited dose-limiting lethality above 8 mg/kg. In HT-29 and MIA PaCa-2 xenografts, BIX-01294 (40 mg/kg) achieved up to 70.6% tumor growth inhibition (TGI), substantially surpassing UNC0642. Furthermore, in MC38 syngeneic models, a BIX-01294/anti-PD-L1 antibody combination produced an additive effect. This combination markedly increased the number of tumor-infiltrating CD8α+ T cells and NK1.1+ cells.
Conclusions:
These results suggest that BIX-01294 is more effective in vivo than UNC0642 due to its favorable PK profile and superior cellular uptake. Our findings support the further development of EHMT2 inhibitors as potent partners for immune checkpoint blockades.
Insights
BIX-01294 shows superior in vivo efficacy compared to UNC0642, with better pharmacokinetics and antitumor activity. This EHMT2 inhibitor is a promising candidate for cancer therapy and combination with immune checkpoint blockade.
Area of Science:
- Epigenetics
- Pharmacology
- Cancer Biology
Background:
- EHMT2 (G9a) is a crucial epigenetic regulator often overexpressed in cancers.
- Existing EHMT2 inhibitors lack comprehensive in vivo efficacy and pharmacokinetic data.
Purpose of the Study:
- To compare the in vivo performance of two EHMT2 inhibitors, BIX-01294 and UNC0642.
- To evaluate their antitumor efficacy and pharmacokinetic profiles in preclinical cancer models.
Main Methods:
- Biochemical, cellular, and pharmacokinetic profiling of BIX-01294 and UNC0642.
- Antitumor efficacy assessment in xenograft (HT-29, MIA PaCa-2) and syngeneic (MC38) mouse models.
- Combination therapy evaluation with anti-PD-L1 in MC38 models.
Main Results:
- BIX-01294 exhibited superior cellular growth inhibition and intracellular accumulation despite lower enzymatic potency than UNC0642.
- BIX-01294 demonstrated better pharmacokinetic exposure and a wider therapeutic window, while UNC0642 showed dose-limiting toxicity.
- BIX-01294 achieved significant tumor growth inhibition (up to 70.6%) in xenografts and enhanced immune cell infiltration when combined with anti-PD-L1 in syngeneic models.
Conclusions:
- BIX-01294 is more effective in vivo than UNC0642, attributed to its favorable pharmacokinetics and cellular uptake.
- EHMT2 inhibitors like BIX-01294 hold potential as combination partners for immune checkpoint blockade therapies.
